Clinical trialNCT02567422Active, not recruitingPhase 1Interventional

Testing the Addition of M6620 (VX-970, Berzosertib) to Usual Chemotherapy and Radiation for Head and Neck Cancer

SponsorNational Cancer Institute (NCI)Enrollment43Head and Neck Carcinoma of Unknown PrimaryHead and Neck Squamous Cell CarcinomaStage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7+6 more conditions

View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Taofeek K Owonikoko
JHU Sidney Kimmel Comprehensive Cancer Center LAO
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

19 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

City of Hope Comprehensive Cancer Center
Duarte, California, United States
University of California Davis Comprehensive Cancer Center
Sacramento, California, United States
Smilow Cancer Center/yale-New Haven Hospital
New Haven, Connecticut, United States
Yale University
New Haven, Connecticut, United States
Smilow Cancer Hospital Care Center-Trumbull
Trumbull, Connecticut, United States
Emory University Hospital Midtown
Atlanta, Georgia, United States
Emory University Hospital/winship Cancer Institute
Atlanta, Georgia, United States
University of Iowa/holden Comprehensive Cancer Center
Iowa City, Iowa, United States
University of Kentucky/markey Cancer Center
Lexington, Kentucky, United States
Johns Hopkins University/sidney Kimmel Cancer Center
Baltimore, Maryland, United States
University of Maryland/greenebaum Cancer Center
Baltimore, Maryland, United States
Wayne State University/karmanos Cancer Institute
Detroit, Michigan, United States
Dartmouth Hitchcock Medical Center/dartmouth Cancer Center
Lebanon, New Hampshire, United States
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, United States
Case Western Reserve University
Cleveland, Ohio, United States
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
University of Pittsburgh Cancer Institute (upci)
Pittsburgh, Pennsylvania, United States
University of Virginia Cancer Center
Charlottesville, Virginia, United States
University of Wisconsin Carbone Cancer Center - University Hospital
Madison, Wisconsin, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 17 Apr 2017
Primary completion: 31 Dec 2023
Completion: 14 May 2027
Last update posted: 2 Jun 2026
Registered enrollment: 43
Registry id: NCT02567422

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.